AVALO THERAPEUTICS, INC. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
AVALO THERAPEUTICS, INC. (AVTX) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of $64 for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2017-11-07
- AVALO THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-09-30 was $64.00.
- AVALO THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-06-30 was $2.11K, a 97.67% decline year-over-year.
- AVALO THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-03-31 was -$3.76K.
- AVALO THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-09-30 was -$101.25K.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month |
|---|---|---|---|
| 2017-09-30 | $64.00 10-Q · filed 2017-11-07 | $2.17K derived: sum of 2 quarters · filed 2017-11-07 | -$1.59K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $2.11K 10-Q · filed 2017-08-14 | -$1.65K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$3.76K 10-Q · filed 2017-05-09 | ||
| 2016-09-30 | -$101.25K 10-Q · filed 2017-11-07 | -$10.49K derived: sum of 2 quarters · filed 2017-11-07 | -$57.59K 10-Q · filed 2017-11-07 |
| 2016-06-30 | $90.75K 10-Q · filed 2017-08-14 | $43.65K 10-Q · filed 2017-08-14 | |
| 2016-03-31 | -$47.10K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |